Guidance confirmed
- In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5 . Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6
- Sanofi intends to complete a share buyback program in 2025 of €5 billion of which 72% was already repurchased